Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Up – Still a Buy?

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) gapped up before the market opened on Tuesday . The stock had previously closed at $8.54, but opened at $8.92. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $8.9450, with a volume of 5,305 shares trading hands.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

The company has a current ratio of 6.44, a quick ratio of 5.74 and a debt-to-equity ratio of 0.01. The firm’s fifty day moving average price is $8.38 and its 200 day moving average price is $8.55. The firm has a market capitalization of $15.21 billion, a PE ratio of 13.97, a P/E/G ratio of 2.01 and a beta of 0.19.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last posted its earnings results on Monday, October 27th. The company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.16 by $0.02. The company had revenue of $740.85 million during the quarter, compared to the consensus estimate of $742.35 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 39.53% and a return on equity of 11.90%. As a group, equities analysts forecast that Shionogi & Co., Ltd. Unsponsored ADR will post 0.66 earnings per share for the current year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.